MMED (NASDAQ:MMED) Earns Outperform Rating from Analysts at Mizuho

Research analysts at Mizuho began coverage on shares of MMED (NASDAQ:MMED) in a report released on Tuesday. The brokerage set an “outperform” rating and a $21.00 price target on the stock. Mizuho’s price target would indicate a potential upside of 46.34% from the company’s previous close.

A number of other equities analysts also recently issued reports on the stock. Wall Street Zen upgraded shares of MMED to a “hold” rating in a report on Saturday, March 14th. Piper Sandler began coverage on shares of MMED in a research report on Tuesday. They set a “neutral” rating and a $16.00 target price on the stock. Bank of America started coverage on shares of MMED in a report on Tuesday. They issued a “buy” rating and a $27.00 target price for the company. Finally, BTIG Research assumed coverage on MMED in a research note on Tuesday. They set a “buy” rating and a $25.00 price target on the stock. Nine equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $22.33.

MMED Trading Down 0.8%

NASDAQ:MMED opened at $14.35 on Tuesday. MMED has a 1 year low of $14.10 and a 1 year high of $20.48.

About MMED

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.